Clinical Trials Logo

Estrogen Receptor Status clinical trials

View clinical trials related to Estrogen Receptor Status.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02860000 Active, not recruiting - Clinical trials for Stage IV Breast Cancer

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

Start date: July 6, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

NCT ID: NCT02414646 Active, not recruiting - Clinical trials for Stage IIIC Breast Cancer AJCC v7

Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer

Start date: April 10, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well trastuzumab emtansine works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive stage I-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability grow and spread.